biotech

95992888

Did Biogen Run Too Much After Earnings?

Biogen Idec Inc. (NASDAQ: BIIB) announced its fourth-quarter financials Thursday after the markets closed. The company reported revenue of $2.6 billion, up 34% from the fourth quarter of the previous year. Revenues ...
Read Full Story »
Money background. Close-up.

Is Celgene’s Outlook Good Enough for Investors?

Celgene Corp. (NASDAQ: CELG) reported its fourth-quarter results on Thursday morning. The biotech giant did beat earnings, but investors have to weigh whether it was enough when you consider that ...
Read Full Story »
Biotechnology word cloud

Short Sellers Starting to Gang Up on Biotech

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Shake Shack IPO

Shake Shack Leads the Parade of IPOs Scheduled for Next Week

Initial public offerings (IPO) were a bit slow getting off the mark in 2015, but the week of January 26 looks ready to make up for the tepid start. A ...
Read Full Story »
research

3 Biotech Stocks With Upcoming Data That Could Be Huge

Binary events are often the key element in moving a biotech stock higher. Negative binary results or actions can often move shares drastically lower, though. We scan our 24/7 Wall ...
Read Full Story »
health care

Did Ziopharm and Intrexon Run Too Much on an MD Anderson Pact?

When two stocks run up over 50% and 30% on the same news, investors have to wonder if the move in the stock was justified or if the news-pop was ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
462542665

Celgene Expects to More Than Triple Earnings by 2020

Celgene Corp. (NASDAQ: CELG) provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare ...
Read Full Story »
payoff

Is the Merger a Great Deal for Tekmira Shareholders?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), in conjunction with OnCore Biopharma, announced that they have agreed to merge and create a new global hepatitis B virus (HBV) company. The focus of ...
Read Full Story »
DNA

Has Agenus Run Too Much?

Agenus Inc. (NASDAQ: AGEN), in conjunction with Incyte Corp. (NASDAQ: INCY), announced a global license for the development and commercialization of Agenus’s proprietary Retrocyte Display antibody discovery platform. As a ...
Read Full Story »
biotech

Analyst’s Top 3 Biotech Picks for 2015 With Upside and Takeover Potential

With a strong market rally getting the markets just about back to even to the start of 2015, aggressive investors are looking ahead to fourth-quarter earnings and other catalysts to ...
Read Full Story »
DNA

6 Serious Biotech and Health Care Movers

In Thursday morning’s trading session, it seemed almost across the board that biotech stocks were the largest gainers. The broad markets were signaling optimism Thursday after a lackluster week, and ...
Read Full Story »
Biotechnology word cloud

Wells Fargo’s Top Biotech Stocks for 2015

Looking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo ...
Read Full Story »
Pills

Analyst’s 8 Top Health Care Stocks for 2015

Health care had an outstanding year in 2014. In fact the sector through last Friday was up 23.30%, which placed it third in the S&P 500 sector race, just behind ...
Read Full Story »
research

New Biotech ETF Hits the Market

The ALPS Medical Breakthroughs ETF (NYSEMKT: SBIO) debuted on the market Wednesday, December 31, 2014. This exchange traded fund will track the Poliwogg Medical Breakthroughs Index (PMBI), which is designed ...
Read Full Story »